MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured,

GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results

2026/02/16 22:31
2 min read

MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ — GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year 2025 following the close of market on Thursday, Feb. 19, 2026. Following the release, company management will host a webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and business progress.

Fourth Quarter and Full Year 2025 Webcast and Conference Call Details

A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL’s website at investors.grail.com.  

Please register for the live event at https://grail-q4-financial-results-2025.open-exchange.net/

To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL’s targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-fourth-quarter-and-full-year-2025-financial-results-302688442.html

SOURCE GRAIL, Inc.

Market Opportunity
Camelot Token Logo
Camelot Token Price(GRAIL)
$77.54
$77.54$77.54
-0.55%
USD
Camelot Token (GRAIL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.